Zura Bio Limited, a clinical-stage immunology company, has announced the launch of TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS). This study is the first to assess the dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in this patient population. The 28-week study will include a 16-week primary efficacy assessment and a 12-week safety follow-up, with an optional open-label extension. Approximately 180 participants will be enrolled across clinical sites in the United States, Canada, and Europe. Topline results for the primary efficacy endpoint are anticipated in the third quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.